Cargando…
Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway
BACKGROUND: Radiotherapy plays an important role in the treatment of prostate cancer. Despite that sophisticated techniques of radiotherapy and radiation combined with chemotherapy were applied to the patients, some tumors may recur. Therefore, the study investigated the effect of dihydroisotanshino...
Autores principales: | Lee, I-Yun, Lin, Yin-Yin, Yang, Yao-Hsu, Lin, Yu-Shin, Lin, Chun-Liang, Lin, Wei-Yu, Cheng, Yu-Ching, Shu, Li-Hsin, Wu, Ching-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793371/ https://www.ncbi.nlm.nih.gov/pubmed/29386061 http://dx.doi.org/10.1186/s40360-018-0195-4 |
Ejemplares similares
-
Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway
por: Wu, Ching-Yuan, et al.
Publicado: (2017) -
Induction of ferroptosis and apoptosis in endometrial cancer cells by dihydroisotanshinone I
por: Wu, Ching-Yuan, et al.
Publicado: (2023) -
Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells
por: Lin, Yu-Shih, et al.
Publicado: (2019) -
Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas
por: Hsu, Cheng-Ming, et al.
Publicado: (2021) -
Dihydroisotanshinone I and BMAL-SIRT1 Pathway in an In Vitro 6-OHDA-Induced Model of Parkinson’s Disease
por: Su, Hui-Chen, et al.
Publicado: (2023)